Immunocore Holdings plc. (IMCR) NASDAQ
$64.38 0.80 (1.26%)
Market Cap: $3.17B
As of 03/28/24 03:15 PM EDT. Market open.
Immunocore Holdings plc. (IMCR)
NASDAQ
$64.38
0.80 (1.26%)
Market Cap: $3.17B
As of 03/28/24 03:15 PM EDT. Market open.
immunocore is a privately owned biotechnology company developing innovative biological therapeutics for the treatment of a range of serious diseases. its world-leading t cell receptor technology exploits the power of the body’s own immune system to find and kill diseased cells. immunocore has established a robust technology platform which combines monoclonal t cell receptor (mtcr) targeting ... read more
immunocore is a privately owned biotechnology company developing innovative biological therapeutics for the treatment of a range of serious diseases. its world-leading t cell receptor technology exploits the power of the body’s own immune system to find and kill diseased cells. immunocore has established a robust technology platform which combines monoclonal t cell receptor (mtcr) targeting technology with an effector technology, anti-cd3 scfv, that catalyses the killing of the targeted diseased cells by the host’s own non-specific cytotoxic t cells. immunocore is developing a portfolio of products from the platform, called immtacs, for the treatment of cancer, chronic infectious disease and diabetes. read less
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
Berman David M | HEAD OF R&D | Feb 28, 2024 | Option Exercise | $17.46 | 36,509 | 637,447 | 36,509 | Mar 01, 2024, 04:15 PM |
Berman David M | HEAD OF R&D | Feb 28, 2024 | Sale | $68.59 | 36,509 | 2,504,159 | 19,609 | Mar 01, 2024, 04:15 PM |
Berman David M | HEAD OF R&D | Feb 27, 2024 | Option Exercise | $17.46 | 54,938 | 959,217 | 54,938 | Feb 28, 2024, 04:15 PM |
Berman David M | HEAD OF R&D | Feb 26, 2024 | Option Exercise | $17.46 | 28,553 | 498,535 | 28,553 | Feb 28, 2024, 04:15 PM |
Berman David M | HEAD OF R&D | Feb 27, 2024 | Sale | $70.86 | 54,938 | 3,893,030 | 50,490 | Feb 28, 2024, 04:15 PM |
Berman David M | HEAD OF R&D | Feb 26, 2024 | Sale | $70.65 | 28,553 | 2,017,288 | 2,037 | Feb 28, 2024, 04:15 PM |
St Leger Tina Amber | Chief HR Officer | Jan 03, 2024 | Option Exercise | $29.87 | 4,375 | 130,681 | 4,375 | Jan 05, 2024, 04:17 PM |
St Leger Tina Amber | Chief HR Officer | Jan 03, 2024 | Sale | $69.89 | 4,375 | 305,781 | 307 | Jan 05, 2024, 04:17 PM |
Owner | Relationship | Date | Value($) |
Berman David M | HEAD OF R&D | 02/28/2024 | 637,447 |
Berman David M | HEAD OF R&D | 02/28/2024 | 2,504,159 |
Berman David M | HEAD OF R&D | 02/27/2024 | 959,217 |
Berman David M | HEAD OF R&D | 02/26/2024 | 498,535 |
Berman David M | HEAD OF R&D | 02/27/2024 | 3,893,030 |
Berman David M | HEAD OF R&D | 02/26/2024 | 2,017,288 |
St Leger Tina Amber | Chief HR Officer | 01/03/2024 | 130,681 |
St Leger Tina Amber | Chief HR Officer | 01/03/2024 | 305,781 |
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
BAKER BROS. ADVISORS LP | 2,452,871 | 1.89% | -2.69% | Other |
BLACKROCK INC. | 779,031 | 0.00136% | 2.53% | Other |
RENAISSANCE TECHNOLOGIES LLC | 345,100 | 0.04% | -24.37% | Other |
CANDRIAM S.C.A. | 144,006 | 0.07% | -50.85% | Other |
HOLOCENE ADVISORS, LP | 165,357 | 0.04% | Exited | Growth At A Reasonable Price |
D. E. SHAW & CO., INC. | 84,653 | 0.00505% | -38.84% | Other |
UBS OCONNOR LLC | 27,641 | 0.14% | -29.75% | Value |
ALPS ADVISORS INC | 33,390 | 0.02% | -7.68% | Other |
GEODE CAPITAL MANAGEMENT, LLC | 26,029 | 0.00019% | 6.72% | Other |
UBS OCONNOR LLC | 25,000 (Call) | 0.02% | New | Value |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 20,000 | 0.00283% | New | Other |
Period of Report: 12/31/2023
10-K/10-Q Filings: View